Stocks Health care ERAS
NASDAQ · Health careErasca, Inc. (ERAS)
It posted a net loss of $287.2M. In fiscal 2025 capital spending exceeded operating cash flow by $95.6M. At June 30, 2026 it held $42.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Key facts about Erasca, Inc.
- Net worth
- Erasca, Inc. has a market value (market cap) of $5.4B at the latest share price, and shareholders' equity of $361.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $95.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 11, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Erasca, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Erasca, Inc. does
Erasca, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ERAS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$124.5M | -$0.44 | -$95.6M |
| 2024 | n/a | -$161.7M | -$0.69 | -$109.5M |
| 2023 | n/a | -$125M | -$0.83 | -$103M |
| 2022 | n/a | -$242.8M | -$1.99 | -$117.8M |
| 2021 | n/a | -$122.8M | -$1.85 | -$90.8M |
| 2021 | n/a | -$101.7M | -$4.83 | -$33.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Erasca, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 16, 2026
- August 24, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
- August 11, 2026
- August 10, 2026
- July 14, 2026Other event 8-K
- July 13, 2026Other event 8-K
- July 13, 2026
Insider trades
What the people running Erasca, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| April 1, 2026 | Garner EbunChief Legal Officer | Exercised options | 80,000 | $136K |
| April 1, 2026 | Garner EbunChief Legal Officer | Soldpre-planned (10b5-1) | 80,000 | $1.3M |
| March 4, 2026 | Morris ShannonChief Medical Officer | Exercised options | 20,000 | $34K |
| March 4, 2026 | Morris ShannonChief Medical Officer | Soldpre-planned (10b5-1) | 20,000 | $300.8K |
| January 7, 2026 | Garner EbunGeneral Counsel & Corp. Sec. | Exercised options | 120,000 | $204K |
| January 7, 2026 | Garner EbunGeneral Counsel & Corp. Sec. | Soldpre-planned (10b5-1) | 120,000 | $670.8K |
| December 15, 2025 | Chacko David M.CFO and CBO | Other change | 17,793 | $21.3K |
| December 15, 2025 | Garner EbunGeneral Counsel & Corp. Sec. | Received as pay | 3,902 | $4.7K |
Who owns ERAS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Jonathan E. Lim13G, passive with 2 related filers | 10.4% | August 14, 2026 |
| T. Rowe Price Investment Management, Inc.13G, passive | 6.8% | May 15, 2026 |
| Frazier Life Sciences Public Fund, L.P.13G, passive with 16 related filers | 5.3% | August 14, 2025 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 5.3% | May 15, 2026 |
| RTW Investments, LP13G, passive with 1 related filers | 5.2% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 257 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 24,975,188 | +300,000 |
| BlackRock, Inc. | 21,154,146 | +1,002,740 |
| Rtw Investments, LP | 17,946,754 | +1,789,579 |
| Venrock Adviser, LLC | 17,891,812 | +1,509,000 |
| State Street Corp | 12,184,555 | +2,884,471 |
| Logos Global Management LP | 12,150,000 | +1,000,000 |
| Vanguard Capital Management LLC | 11,402,199 | +152,461 |
| Siren, L.L.C. | 11,397,781 | +153,535 |
| Paradigm Biocapital Advisors LP | 9,550,000 | -842,702 |
| ARCH Venture Management, LLC | 7,091,557 | 0 |
| Geode Capital Management, LLC | 6,501,426 | +505,277 |
| Cormorant Asset Management, LP | 6,000,000 | +200,000 |
| Affinity Asset Advisors, LLC | 5,250,000 | -100,000 |
| Vivo Capital, LLC | 4,127,412 | -8,024,068 |
| Goldman Sachs Group Inc | 3,822,113 | -1,053,073 |
| Alliancebernstein L.P. | 4,118,614 | +1,473,694 |
| Bank of America Corp | 3,048,737 | -7,160 |
| Fmr LLC | 2,883,417 | +1,393,337 |
| a16z Capital Management, L.L.C. | 2,862,500 | 0 |
| Woodline Partners LP | 2,831,867 | +329 |
Insiders
2 insiders reported holding 305,056 shares in total, about $4.7M at the last price.
| Holder | Shares |
|---|---|
| Chacko David M.CFO and CBO | 279,980 |
| Garner EbunChief Legal Officer | 25,076 |
Questions about ERAS
What does Erasca, Inc. do?
Erasca, Inc. is a company in the Health care sector, listed on NASDAQ as ERAS. Its shares trade on NASDAQ under the ticker ERAS.
What is Erasca, Inc.'s net worth?
Erasca, Inc. has a market value (market cap) of $5.4B at the latest share price, and shareholders' equity of $361.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Erasca, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $287.2M.
When did Erasca, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from October 16, 2026.
When is Erasca, Inc.'s next earnings report?
Erasca, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ERAS with
Follow ERAS
Get an email when Erasca, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Erasca, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.